A pulmonologist discusses the history and influence of race-based reference equations in pulmonary function testing interpretation and patient care.

Italy: A new cross-sectional study published in Respiratory Research has highlighted a significant association between vertebral fractures and impaired lung function in patients with ...

Post-treatment lung health is a longitudinal survivorship issue; nonregenerative parenchymal loss, radiation fibrosis, and systemic-therapy injury justify ongoing symptom reporting, CT/PFT ...

An updated December 2025 ERS clinical practice guideline provides evidence-based recommendations for managing adult ...

Dosing is now underway in an IPF clinical trial testing the inhaled therapy LTI-03, following the lifting of an FDA hold late last year.

Although e-cigarettes are often considered safer than conventional cigarettes, their vapor still poisons lung cells and ...

Dermatomyositis is a rare autoimmune disease that typically affects the skin, muscle and respiratory system. Patients with dermatomyositis usually require prompt treatment with intense ...

MannKind Corp (MNKD) reports a 46% revenue increase and outlines future growth strategies amid challenges in the pulmonary market.

Columnist Sam Kirton has developed some strategies to make the roughly 90-minute commute to his IPF doctor appointments more manageable.

SpliSense, a clinical-stage biotechnology company developing transformative RNA-based therapies for pulmonary diseases, today announced that the European Medicines Agency (EMA) has granted early ...

Cystic fibrosis care is changing quickly — with better treatments, longer lives, and new tools like telehealth. This is pushing us to rethink what high quality, individualized care should look like.

This article originally published at $11M luxury sports, entertainment complex to transform Central Texas.